Pharmacogenomics and bioinformatics: PharmGKB
نویسندگان
چکیده
منابع مشابه
Exploring the Pharmacogenomics Knowledge Base (PharmGKB) for Repositioning Breast Cancer Drugs by Leveraging Web Ontology Language (OWL) and Cheminformatics Approaches
Computational drug repositioning leverages computational technology and high volume of biomedical data to identify new indications for existing drugs. Since it does not require costly experiments that have a high risk of failure, it has attracted increasing interest from diverse fields such as biomedical, pharmaceutical, and informatics areas. In this study, we used pharmacogenomics data genera...
متن کاملBioinformatics and Pharmacogenomics in Drug Discovery and Development - A Socio-Economic Perspective
4 Chapter 1: Introduction 6 Chapter 2: Background and Significance 10 Chapter 3: Problem Statement and Purpose 20 Chapter 4: Methods and Design 24 Chapter 5: Results 31 Chapter 6: Discussion and Future Work 56 Acknowledgements 65 References 66
متن کاملPharmGKB summary: phenytoin pathway.
Phenytoin is one of the most widely prescribed antiepileptic drugs (AEDs) in the USA (approximately 52% of AED prescriptions compared with 19% for valproic acid, 11% carbamazepine, and 7% phenobarbital) [1]. It has a narrow therapeutic range and wide interindividual variability in clearance and, as such, therapeutic drug monitoring is often necessary. Adverse effects of phenytoin range from min...
متن کاملPharmGKB summary: tramadol pathway.
Departments of Genetics, Bioengineering, Stanford University, Stanford, California, USA, Department of Anaesthesiology and Pain Medicine, Inselspital, Department of Clinical Research, University of Bern, Bern, Switzerland and Institute of Clinical Pharmacology, University Medical Center, Göttingen, Germany Correspondence to Teri E. Klein, PhD, Department of Genetics, Stanford University Medical...
متن کاملPharmGKB summary: cyclosporine and tacrolimus pathways.
Tacrolimus (FK506) and cyclosporine (cyclosporin A, CsA) are cornerstone immunosuppressive agents administered to solid organ transplant recipients to prevent and treat allograft rejection. The discovery of cyclosporine in the 1970s, and its entry into the collection of immunosuppressants in the early 1980s, was a major breakthrough in medicine. Cyclosporine was the most successful antirejectio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacogenomics
سال: 2010
ISSN: 1462-2416,1744-8042
DOI: 10.2217/pgs.10.15